List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. Europe Biosimilars Market, 2019-2030, $ mn 19
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019 20
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 20
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area 21
Figure 8. Impact of COVID-19 on Business 25
Figure 9. Primary Drivers and Impact Factors of Europe Biosimilars Market 27
Figure 10. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 12. Primary Restraints and Impact Factors of Europe Biosimilars Market 32
Figure 13. Investment Opportunity Analysis 36
Figure 14. Porter’s Fiver Forces Analysis of Europe Biosimilars Market 39
Figure 15. Breakdown of Europe Biosimilars Market by Product Type, 2019-2030, % of Revenue 44
Figure 16. Europe Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%) 44
Figure 17. Europe Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn 45
Figure 18. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn 47
Figure 19. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn 48
Figure 20. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn 49
Figure 21. Europe Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn 50
Figure 22. Europe Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn 51
Figure 23. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn 52
Figure 24. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn 53
Figure 25. Europe Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn 54
Figure 26. Europe Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn 55
Figure 27. Europe Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn 56
Figure 28. Europe Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn 57
Figure 29. Europe Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn 58
Figure 30. Breakdown of Europe Biosimilars Market by Indication, 2019-2030, % of Sales Revenue 60
Figure 31. Europe Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%) 60
Figure 32. Europe Biosimilars Market by Indication: Cancer, 2019-2030, $ mn 61
Figure 33. Europe Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn 62
Figure 34. Europe Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn 63
Figure 35. Europe Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn 64
Figure 36. Europe Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn 65
Figure 37. Europe Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn 66
Figure 38. Europe Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn 67
Figure 39. Breakdown of Europe Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue 69
Figure 40. Europe Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%) 69
Figure 41. Europe Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn 70
Figure 42. Europe Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn 71
Figure 43. Breakdown of Europe Biosimilars Market by End User, 2019-2030, % of Revenue 73
Figure 44. Europe Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%) 73
Figure 45. Europe Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn 74
Figure 46. Europe Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn 75
Figure 47. Europe Biosimilars Market by End User: Other End Users, 2019-2030, $ mn 76
Figure 48. Breakdown of European Biosimilars Market by Country, 2019 and 2030, % of Revenue 78
Figure 49. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%) 79
Figure 50. Biosimilars Market in Germany, 2019-2030, $ mn 82
Figure 51. Biosimilars Market in U.K., 2019-2030, $ mn 85
Figure 52. Biosimilars Market in France, 2019-2030, $ mn 88
Figure 53. Biosimilars Market in Spain, 2019-2030, $ mn 90
Figure 54. Biosimilars Market in Italy, 2019-2030, $ mn 92
Figure 55. Biosimilars Market in Russia, 2019-2030, $ mn 94
Figure 56. Biosimilars Market in Rest of Europe, 2019-2030, $ mn 96
Figure 57. Growth Stage of Europe Biosimilars Industry over the Forecast Period 98
Europe biosimilars market was valued at $5,847.6 million in 2020 and will grow by 23.1% annually over 2020-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions. Highlighted with 37 tables and 57 figures, this 121-page report “Europe Biosimilars Market 2020-2030 by Product Type (Non-glycosylated, Glycosylated), Indication (Cancer, Autoimmune Disease, Blood Disorder, Diabetes), Manufacturing (Contract, Inhouse), End User (Hospitals and Clinics, Research Institutes), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe biosimilars market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Country. Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Recombinant Non-glycosylated Biosimilars • Insulin • Recombinant Human Growth Hormone (rHGH) • Granulocyte Colony Stimulating Factor • Interferon • Recombinant Glycosylated Biosimilars • Monoclonal Antibodies (mAb) • Erythropoietin (EPO) • Follicle Stimulating Hormone • Recombinant Peptides and Others • Tumor Necrosis Factor (TNF)-Inhibitor • Parathyroid Hormone • Enzymes, Immunomodulators, GnRH Analogs and Others Based on Indication, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Cancer • Autoimmune Disease • Blood Disorder • Diabetes • Growth Hormone Deficiency • Infectious Diseases • Other Indications Based on Manufacturing, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Contract Manufacturing • Inhouse Manufacturing Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Hospitals and Clinics • Research Institutes • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Product Type, Indication, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AMEGA Biotech S.A. Apotex Inc. Biocon Ltd Biogen Inc. Boehringer Ingelheim Celltrion, Inc. Dr. Reddy’s Laboratories Ltd. Eli Lilly and Company Intas Pharmaceuticals Ltd. LG Chem, Ltd. Merck and Co. Inc. Mylan N.V. Pfizer Inc. Samsung Biologics Co., Ltd. Sandoz International GmbH STADA Arzneimittel AG Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More